Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China · Delayed Price · Currency is CNY 54.20
-0.64 (-1.17%)
Nov 13, 2026, 3:00 PM CST
SHA:688621 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,012 | 1,222 | 1,078 | 932.12 | 676.61 | 493.65 |
Revenue Growth | -0.57% | 13.33% | 15.70% | 37.76% | 37.06% | 42.12% |
Gross Profit Gross Profit Growth | 514.13 | 661.45 | 541.14 | 528.35 | 375.46 | 263.68 |
Operating Income Operating Income Growth | 36.71 | 209.23 | 176.32 | 193.46 | 156.14 | 119.97 |
Net Income Net Income Growth | 6.04 | 203.87 | 177.41 | 184.76 | 156.47 | 105.66 |
Earnings Per Share EPS Growth | 0.05 | 1.86 | 1.58 | 1.65 | 1.40 | 1.08 |
EPS Growth | -95.49% | 17.72% | -4.24% | 17.86% | 29.80% | 24.80% |
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Innovative Drugs and Improved New Drugs Innovative Drugs and Improved New Drugs Growth | 248.36 | - | - | - |
Clinical Trials and Bioanalytical Services Clinical Trials and Bioanalytical Services Growth | 522.56 | 511.65 | 362.39 | 234.5 |
Pharmacy Research Services Pharmacy Research Services Growth | 338.48 | 558.68 | 568.6 | 441.9 |
Equity Sharing Equity Sharing Growth | 10.94 | 6.53 | - | - |
Intellectual Property Licensing Intellectual Property Licensing Growth | 100 | - | - | - |
Total Total Growth | 1,220 | 1,077 | 930.98 | 676.39 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 533 | 617.17 | 615.56 | 720.93 | 622.04 | 647.85 |
Total Debt Total Debt Growth | 712.72 | 613.71 | 455.79 | 446.65 | 257.55 | 206.71 |
Net Cash (Debt) Net Cash Growth | -179.72 | 3.45 | 159.77 | 274.28 | 364.48 | 441.14 |
Net Cash Growth | - | -97.84% | -41.75% | -24.75% | -17.38% | 414.12% |
Net Cash Per Share Net Cash Per Share Growth | -1.62 | 0.03 | 1.42 | 2.45 | 3.26 | 4.50 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -114.02 | 93.21 | 32.02 | 92.86 | 103.96 | 88.25 |
Capital Expenditures CapEx Growth | -50.62 | -42.43 | -30.48 | -72.96 | -103.87 | -84.96 |
Free Cash Flow Free Cash Flow Growth | -164.64 | 50.78 | 1.54 | 19.9 | 0.09 | 3.29 |
Free Cash Flow Growth | - | 3206.74% | -92.28% | 21552.67% | -97.21% | -90.84% |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 50.82% | 54.12% | 50.18% | 56.68% | 55.49% | 53.41% |
Operating Margin | 3.63% | 17.12% | 16.35% | 20.76% | 23.08% | 24.30% |
Pretax Margin | -3.03% | 17.08% | 16.32% | 20.75% | 25.00% | 24.73% |
Profit Margin | 0.60% | 16.68% | 16.45% | 19.82% | 23.13% | 21.40% |
FCF Margin | -16.27% | 4.15% | 0.14% | 2.14% | 0.01% | 0.67% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.187 | 0.187 | 0.163 | 0.165 | 0.429 | 0.189 |
Dividend Per Share Growth | -42.99% | 14.72% | -1.21% | -61.50% | 126.41% | - |
Dividend Yield | 0.34% | 0.30% | 0.43% | 0.24% | 0.59% | 0.22% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 13, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 996.03 | 33.31 | 23.80 | 42.28 | 52.35 | 92.07 |
Forward PE | - | 30.32 | 12.29 | 24.18 | 41.58 | 79.34 |
P/FCF Ratio | - | 133.74 | 2749.41 | 392.53 | 89126.79 | 2953.42 |
PS Ratio | 5.85 | 5.56 | 3.92 | 8.38 | 12.11 | 19.71 |